Orbimed Advisors - Q1 2023 holdings

$5.09 Billion is the total value of Orbimed Advisors's 125 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 37.4% .

 Value Shares↓ Weighting
SVA  SINOVAC BIOTECH LTD$340,000,0000.0%2,718,7350.0%6.67%
+2.6%
NewENLIVEN THERAPEUTICS INC$197,017,0658,996,213
+100.0%
3.87%
BSX SellBOSTON SCIENTIFIC CORP$189,613,700
+5.1%
3,790,000
-2.8%
3.72%
+7.9%
HUM  HUMANA INC$169,279,902
-5.2%
348,7000.0%3.32%
-2.8%
BMY SellBRISTOL-MYERS SQUIBB CO$162,185,400
-12.8%
2,340,000
-9.5%
3.18%
-10.5%
ISRG  INTUITIVE SURGICAL INC$158,519,135
-3.7%
620,5000.0%3.11%
-1.2%
BMRN  BIOMARIN PHARMACEUTICAL INC$157,063,020
-6.0%
1,615,2100.0%3.08%
-3.6%
 THESEUS PHARMACEUTICALS INC$153,034,972
+78.3%
17,233,6680.0%3.00%
+82.9%
BIIB BuyBIOGEN INC$140,405,150
+96.4%
505,000
+95.6%
2.76%
+101.5%
UNH SellUNITEDHEALTH GROUP INC$130,434,840
-35.3%
276,000
-27.5%
2.56%
-33.6%
SRPT SellSAREPTA THERAPEUTICS INC$119,236,733
-5.4%
865,100
-11.0%
2.34%
-2.9%
SWTX SellSPRINGWORKS THERAPEUTICS INC$115,801,686
-15.2%
4,498,900
-14.3%
2.27%
-13.0%
SYK SellSTRYKER CORPORATION$104,938,772
-10.8%
367,600
-23.6%
2.06%
-8.4%
EWTX  EDGEWISE THERAPEUTICS INC$97,163,064
-25.4%
14,567,1760.0%1.91%
-23.4%
EVH BuyEVOLENT HEALTH INCcl a$93,963,258
+18.5%
2,895,632
+2.5%
1.84%
+21.6%
TERN  TERNS PHARMACEUTICALS INC$90,210,558
+16.3%
7,619,1350.0%1.77%
+19.3%
VRNA SellVERONA PHARMA PLCsponsored ads$85,554,675
-28.4%
4,260,691
-6.8%
1.68%
-26.5%
TMO SellTHERMO FISHER SCIENTIFIC INC$85,187,486
-23.5%
147,800
-26.9%
1.67%
-21.5%
IONS BuyIONIS PHARMACEUTICALS INC$75,929,630
+0.8%
2,124,500
+6.6%
1.49%
+3.5%
CMPX  COMPASS THERAPEUTICS INC$73,126,520
-35.0%
22,362,8500.0%1.44%
-33.3%
THC  TENET HEALTHCARE CORP$72,510,226
+21.8%
1,220,3000.0%1.42%
+24.9%
KROS  KEROS THERAPEUTICS INC$71,711,106
-11.1%
1,679,4170.0%1.41%
-8.7%
LLY NewLILLY ELI & CO$63,876,120186,000
+100.0%
1.25%
CRNX BuyCRINETICS PHARMACEUTICALS IN$63,449,784
+8.5%
3,950,796
+23.6%
1.25%
+11.3%
BAX NewBAXTER INTL INC$63,354,7201,562,000
+100.0%
1.24%
APLS NewAPELLIS PHARMACEUTICALS INC$60,036,792910,200
+100.0%
1.18%
SIBN SellSI-BONE INC$57,425,660
+25.4%
2,919,454
-13.3%
1.13%
+28.7%
PRLD  PRELUDE THERAPEUTICS INC$57,226,239
-5.6%
10,039,6910.0%1.12%
-3.2%
SBTX  ARS PHARMACEUTICALS INC$56,903,174
-23.7%
8,740,8870.0%1.12%
-21.7%
VRTX SellVERTEX PHARMACEUTICALS INC$55,956,432
-28.6%
177,600
-34.6%
1.10%
-26.8%
NTRA SellNATERA INC$54,053,217
-30.9%
973,581
-50.0%
1.06%
-29.1%
SellPRELUDE THERAPEUTICS INCnonvoting$53,820,418
+4.5%
11,895,652
-2.1%
1.06%
+7.3%
EW SellEDWARDS LIFESCIENCES CORP$52,119,900
-18.8%
630,000
-26.8%
1.02%
-16.7%
SCPH  SCPHARMACEUTICALS INC$50,424,919
+26.5%
5,559,5280.0%0.99%
+29.8%
NBIX SellNEUROCRINE BIOSCIENCES INC$49,496,580
-39.7%
489,000
-28.9%
0.97%
-38.1%
BuyDISC MEDICINE INC$48,093,608
+11.9%
2,269,637
+5.0%
0.94%
+14.8%
KDNY  CHINOOK THERAPEUTICS INC$46,978,295
-11.6%
2,029,3000.0%0.92%
-9.3%
XTNT  XTANT MED HLDGS INC$46,610,552
-3.4%
73,114,5920.0%0.92%
-0.9%
VECT SellVECTIVBIO HLDG AG$43,882,334
-27.7%
5,156,561
-26.4%
0.86%
-25.8%
ACET  ADICET BIO INC$42,895,526
-35.6%
7,447,1400.0%0.84%
-33.9%
QURE BuyUNIQURE NV$41,578,124
+5.0%
2,064,455
+18.1%
0.82%
+7.7%
XENE  XENON PHARMACEUTICALS INC$41,126,289
-9.2%
1,149,1000.0%0.81%
-6.9%
TVTX BuyTRAVERE THERAPEUTICS INC$39,229,307
+48.9%
1,744,300
+39.2%
0.77%
+52.8%
MRSN  MERSANA THERAPEUTICS INC$37,037,006
-29.9%
9,011,4370.0%0.73%
-28.0%
BLU BuyBELLUS HEALTH INC NEW$36,755,893
-4.9%
5,108,900
+8.5%
0.72%
-2.4%
SNDX SellSYNDAX PHARMACEUTICALS INC$36,150,576
-29.2%
1,711,675
-14.7%
0.71%
-27.3%
JANX  JANUX THERAPEUTICS INC$34,320,271
-8.1%
2,836,3860.0%0.67%
-5.7%
MRTX SellMIRATI THERAPEUTICS INC$33,969,507
-41.6%
913,650
-28.8%
0.67%
-40.1%
PGNY BuyPROGYNY INC$33,337,733
+3.4%
1,037,912
+0.3%
0.65%
+6.0%
RPTX  REPARE THERAPEUTICS INC$32,693,282
-33.1%
3,322,4880.0%0.64%
-31.3%
TELA  TELA BIO INC$32,213,047
-7.5%
3,027,5420.0%0.63%
-5.1%
KNTE BuyKINNATE BIOPHARMA INC$32,147,681
+30.3%
5,143,629
+27.2%
0.63%
+33.7%
ALPN  ALPINE IMMUNE SCIENCES INC$31,509,890
+5.0%
4,081,5920.0%0.62%
+7.8%
ABCL  ABCELLERA BIOLOGICS INC$31,522,991
-25.6%
4,180,7680.0%0.62%
-23.6%
PMVP  PMV PHARMACEUTICALS INC$31,305,877
-45.2%
6,563,0770.0%0.62%
-43.7%
IOVA BuyIOVANCE BIOTHERAPEUTICS INC$28,762,568
+124.2%
4,707,458
+134.5%
0.56%
+130.6%
PCVX SellVAXCYTE INC$27,339,374
-55.6%
729,439
-43.2%
0.54%
-54.4%
NewR1 RCM INC$26,250,0001,750,000
+100.0%
0.52%
Buy2SEVENTY BIO INC$24,394,606
+150.0%
2,391,628
+129.7%
0.48%
+156.1%
NewAMYLYX PHARMACEUTICALS INC$23,868,090813,500
+100.0%
0.47%
 THIRD HARMONIC BIO INC$23,809,773
-4.2%
5,779,0710.0%0.47%
-1.7%
RAPT  RAPT THERAPEUTICS INC$22,957,135
-7.3%
1,251,0700.0%0.45%
-4.9%
HZNP BuyHORIZON THERAPEUTICS PUB L$21,828,000
+12.2%
200,000
+17.0%
0.43%
+15.3%
ARQT SellARCUTIS BIOTHERAPEUTICS INC$21,059,269
-42.2%
1,914,479
-22.2%
0.41%
-40.7%
XBI BuySPDR SER TRs&p biotech$20,881,540
+229.3%
274,000
+258.6%
0.41%
+238.8%
 RXSIGHT INC$20,063,254
+31.6%
1,202,8330.0%0.39%
+34.9%
REGN NewREGENERON PHARMACEUTICALS$19,720,08024,000
+100.0%
0.39%
SellVENTYX BIOSCIENCES INC$19,597,500
-35.4%
585,000
-36.8%
0.38%
-33.6%
NPCE  NEUROPACE INC$18,616,984
+211.4%
4,012,2810.0%0.36%
+220.2%
AMGN NewAMGEN INC$18,542,22576,700
+100.0%
0.36%
GRCL BuyGRACELL BIOTECHNOLOGIES INCsponsored ads$17,665,860
-2.6%
9,497,774
+20.5%
0.35%0.0%
KZR BuyKEZAR LIFE SCIENCES INC$17,099,190
-47.0%
5,463,000
+19.2%
0.34%
-45.5%
ARGX BuyARGENX SEsponsored adr$16,579,810
+170.2%
44,500
+174.7%
0.32%
+177.8%
NewAPOLLOMICS INC$16,033,976662,561
+100.0%
0.32%
AVTE SellAEROVATE THERAPEUTICS INC$15,267,278
-31.4%
756,930
-0.3%
0.30%
-29.6%
DBTX  DECIBEL THERAPEUTICS INC$14,934,480
+47.3%
4,945,1920.0%0.29%
+51.0%
BAX NewBAXTER INTL INCcall$14,196,000350,000
+100.0%
0.28%
GHRS BuyGH RESEARCH PLCordinary shares$13,255,530
-15.9%
1,659,015
+2.3%
0.26%
-13.9%
ALXO  ALX ONCOLOGY HLDGS INC$12,976,920
-59.9%
2,871,0000.0%0.26%
-58.8%
FOLD BuyAMICUS THERAPEUTICS INC$12,986,390
+106.1%
1,171,000
+126.9%
0.26%
+110.7%
SellBRIDGEBIO PHARMA INCnote 2.250% 2/0$12,853,200
+2.0%
20,000,000
-33.3%
0.25%
+4.6%
FUSN SellFUSION PHARMACEUTICALS INC$11,772,843
+15.9%
3,122,770
-3.2%
0.23%
+19.1%
IKNA BuyIKENA ONCOLOGY INC$10,992,273
+40.8%
3,186,166
+8.6%
0.22%
+45.0%
GDRX BuyGOODRX HLDGS INC$10,625,000
+488.3%
1,700,000
+338.6%
0.21%
+497.1%
VERA NewVERA THERAPEUTICS INCcl a$10,572,2241,362,400
+100.0%
0.21%
SRPT NewSAREPTA THERAPEUTICS INCcall$10,337,25075,000
+100.0%
0.20%
BCAB BuyBIOATLA INC$10,347,480
+277.4%
3,861,000
+1061.7%
0.20%
+290.4%
SellBRIDGEBIO PHARMA INCnote 2.500% 3/1$9,468,750
+19.1%
12,500,000
-37.5%
0.19%
+22.4%
PASG  PASSAGE BIO INC$8,554,175
-30.6%
8,931,9990.0%0.17%
-28.8%
GLTO  GALECTO INC$8,140,965
+73.0%
4,090,9370.0%0.16%
+77.8%
ORIC SellORIC PHARMACEUTICALS INC$7,834,468
-17.3%
1,374,468
-14.5%
0.15%
-14.9%
XBI NewSPDR SER TRcall$7,621,000100,000
+100.0%
0.15%
PTGX NewPROTAGONIST THERAPEUTICS INC$6,923,000301,000
+100.0%
0.14%
VSTM  VERASTEM INC$6,852,144
+3.2%
16,503,2370.0%0.14%
+6.3%
NewYS BIOPHARMA CO LTDordinary shares$6,877,5424,298,464
+100.0%
0.14%
IMTX NewIMMATICS N.V$6,536,011947,248
+100.0%
0.13%
 INVIVYD INC$6,324,480
-20.0%
5,270,4000.0%0.12%
-17.9%
CRVS  CORVUS PHARMACEUTICALS INC$6,318,725
+7.1%
6,943,6540.0%0.12%
+9.7%
CGEM SellCULLINAN ONCOLOGY INC$6,193,109
-7.9%
605,387
-5.0%
0.12%
-5.4%
NTLA NewINTELLIA THERAPEUTICS INC$6,135,648164,627
+100.0%
0.12%
MRTX NewMIRATI THERAPEUTICS INCcall$5,577,000150,000
+100.0%
0.11%
MREO SellMEREO BIOPHARMA GROUP PLCspon ads$5,476,984
-31.1%
7,747,891
-26.9%
0.11%
-28.9%
HZNP NewHORIZON THERAPEUTICS PUB Lput$5,457,00050,000
+100.0%
0.11%
XFOR  X4 PHARMACEUTICALS INC$5,061,422
-12.4%
5,817,7260.0%0.10%
-10.8%
 VIGIL NEUROSCIENCE INC$4,394,643
-21.7%
448,8910.0%0.09%
-19.6%
SRRK SellSCHOLAR ROCK HLDG CORP$4,120,000
-48.2%
515,000
-41.4%
0.08%
-46.7%
NXTC  NEXTCURE INC$4,012,299
+5.0%
2,711,0130.0%0.08%
+8.2%
SYBX  SYNLOGIC INC$3,810,957
-16.8%
6,029,9950.0%0.08%
-14.8%
CMMB SellCHEMOMAB THERAPEUTICS LTDsponsored ads$3,563,626
-56.8%
2,241,274
-13.1%
0.07%
-55.7%
EPIX BuyESSA PHARMA INC$3,559,061
+286.6%
1,198,337
+228.0%
0.07%
+288.9%
TARA SellPROTARA THERAPEUTICS INC$2,483,837
+11.6%
793,558
-4.5%
0.05%
+14.0%
BOLT BuyBOLT BIOTHERAPEUTICS INC$2,141,990
+113.7%
1,541,000
+99.9%
0.04%
+121.1%
AFIB  ACUTUS MED INC$1,996,883
-34.4%
2,648,3860.0%0.04%
-32.8%
RVNC NewREVANCE THERAPEUTICS INC$1,610,50050,000
+100.0%
0.03%
HRTX NewHERON THERAPEUTICS INC$1,212,077802,700
+100.0%
0.02%
PHGE BuyBIOMX INC$964,254
+83.6%
3,161,489
+12.4%
0.02%
+90.0%
MRSN NewMERSANA THERAPEUTICS INCcall$865,977210,700
+100.0%
0.02%
NKTR NewNEKTAR THERAPEUTICS$726,8401,034,059
+100.0%
0.01%
OMIC  SINGULAR GENOMICS SYSTEMS IN$654,243
-39.8%
540,6970.0%0.01%
-38.1%
AGLE  AEGLEA BIOTHERAPEUTICS INC$521,194
-35.5%
1,797,2210.0%0.01%
-33.3%
HARP SellHARPOON THERAPEUTICS INC$462,310
-58.0%
621,218
-59.0%
0.01%
-57.1%
NKTR NewNEKTAR THERAPEUTICScall$383,081545,000
+100.0%
0.01%
ALT NewALTIMMUNE INCcall$422,000100,000
+100.0%
0.01%
ALT NewALTIMMUNE INC$213,53250,600
+100.0%
0.00%
GLUE ExitMONTE ROSA THERAPEUTICS INC$0-27,369
-100.0%
-0.00%
MACK ExitMERRIMACK PHARMACEUTICALS IN$0-73,600
-100.0%
-0.02%
ExitPYXIS ONCOLOGY INC$0-848,252
-100.0%
-0.02%
CLXPF ExitCYBIN INC$0-5,386,299
-100.0%
-0.03%
EYPT ExitEYEPOINT PHARMACEUTICALS INC$0-487,642
-100.0%
-0.03%
GRAY ExitGRAYBUG VISION INC$0-4,163,347
-100.0%
-0.04%
APLT ExitAPPLIED THERAPEUTICS INC$0-3,050,921
-100.0%
-0.04%
AMRX ExitAMNEAL PHARMACEUTICALS INC$0-1,583,490
-100.0%
-0.06%
SNY ExitSANOFIcall$0-100,000
-100.0%
-0.09%
BNTX ExitBIONTECH SEsponsored ads$0-36,300
-100.0%
-0.10%
MRNA ExitMODERNA INC$0-82,550
-100.0%
-0.28%
IMRA ExitIMARA INC$0-4,386,568
-100.0%
-0.34%
ExitCINCOR PHARMA INC$0-1,906,000
-100.0%
-0.45%
ACRS ExitACLARIS THERAPEUTICS INC$0-2,758,434
-100.0%
-0.83%
ETNB Exit89BIO INC$0-3,658,869
-100.0%
-0.89%
PFE ExitPFIZER INC$0-1,393,600
-100.0%
-1.37%
SGEN ExitSEAGEN INC$0-913,812
-100.0%
-2.25%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

About Orbimed Advisors

Orbimed Advisors is a leading healthcare-focused investment firm that manages over $16 billion in assets. The firm was founded in 1998 by Samuel Isaly, who has over 50 years of experience in the healthcare industry. Isaly is widely regarded as a pioneer in the field of healthcare investing and has been recognized for his contributions to the industry by numerous organizations.

Orbimed Advisors has a team of over 100 professionals, including investment professionals, research analysts, and operational experts. The firm has offices in New York, San Francisco, Shanghai, and Mumbai, and invests in companies across the healthcare spectrum, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

The firm's investment philosophy is based on a deep understanding of the healthcare industry and a rigorous approach to due diligence. Orbimed Advisors seeks to identify companies with innovative technologies and strong management teams that have the potential to transform the healthcare landscape.

Orbimed Advisors has a strong track record of success, with numerous successful investments in companies such as Juno Therapeutics, Spark Therapeutics, and Kite Pharma. The firm's leadership team, which includes CEO Sven Borho, COO Jonathan Silverstein, and Chief Investment Officer Carl Gordon, has decades of experience in the healthcare industry and is widely respected for their expertise and insights.

Overall, Orbimed Advisors is a leading healthcare investment firm that has a proven track record of success and a deep understanding of the healthcare industry. Investors looking to gain exposure to the healthcare sector may want to consider Orbimed Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BIOGEN INC42Q3 20235.0%
VERTEX PHARMACEUTICALS INC42Q3 20233.7%
THERMO FISHER SCIENTIFIC INC42Q3 20233.2%
SINOVAC BIOTECH LTD41Q3 20237.2%
NEUROCRINE BIOSCIENCES INC41Q3 20232.7%
BOSTON SCIENTIFIC CORP40Q3 20235.6%
BRISTOL-MYERS SQUIBB CO40Q2 20235.2%
AMGEN INC40Q3 20235.5%
INTUITIVE SURGICAL INC40Q3 20233.8%
GILEAD SCIENCES INC39Q3 20235.5%

View Orbimed Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Orbimed Advisors Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Ikena Oncology, Inc.September 21, 20232,189,1115.2%
Galecto, Inc.September 18, 2023749,5572.8%
PMV Pharmaceuticals, Inc.August 23, 20236,563,07713.5%
Gracell Biotechnologies Inc.August 11, 20237,641,5318.0%
Xtant Medical Holdings, Inc.August 03, 202373,114,59256.7%
Turnstone Biologics Corp.July 24, 20233,099,26513.4%
Passage BIO, Inc.June 29, 20238,034,00014.7%
Prelude Therapeutics IncMay 24, 202315,716,64228.6%
VectivBio Holding AGMay 24, 20235,156,5617.7%
Fusion Pharmaceuticals Inc.May 16, 20232,930,6704.6%

View Orbimed Advisors's complete significant-ownership history.

Latest filings
TypeFiled
32024-03-27
SC 13D/A2024-03-22
SC 13D/A2024-03-21
SC 13D/A2024-03-08
1442024-03-04
SC 13D/A2024-02-21
13F-HR2024-02-14
42024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Orbimed Advisors's complete filings history.

Compare quarters

Export Orbimed Advisors's holdings